NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.62
+0.28 (2.47%)
At close: Aug 13, 2025, 4:00 PM
11.51
-0.11 (-0.95%)
Pre-market: Aug 14, 2025, 9:04 AM EDT
NovoCure Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for NovoCure stock ranges from a low of $14.5 to a high of $38. The average analyst price target of $28.79 forecasts a 147.76% increase in the stock price over the next year.
Price Target: $28.79 (+147.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 1 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $40 → $15 | Buy → Hold | Downgrades | $40 → $15 | +24.78% | Jul 25, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +158.18% | Jul 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $34 | Buy | Reiterates | $34 | +192.60% | Jun 27, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $34 | Buy | Maintains | $42 → $34 | +192.60% | Apr 23, 2025 |
| Wedbush | Wedbush | Hold Maintains $29 → $27 | Hold | Maintains | $29 → $27 | +132.36% | Apr 16, 2025 |
Financial Forecast
Revenue This Year
642.45M
from 605.22M
Increased by 6.15%
Revenue Next Year
689.69M
from 642.45M
Increased by 7.35%
EPS This Year
-1.67
from -1.56
EPS Next Year
-1.82
from -1.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 670.0M | 749.3M | 903.0M | ||
| Avg | 642.5M | 689.7M | 810.3M | ||
| Low | 605.2M | 637.9M | 699.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.7% | 16.6% | 30.9% | ||
| Avg | 6.2% | 7.4% | 17.5% | ||
| Low | -0.0% | -0.7% | 1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.62 | -1.45 | -1.10 | ||
| Avg | -1.67 | -1.82 | -1.43 | ||
| Low | -1.74 | -2.05 | -1.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.